JP2006516977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516977A5 JP2006516977A5 JP2006500937A JP2006500937A JP2006516977A5 JP 2006516977 A5 JP2006516977 A5 JP 2006516977A5 JP 2006500937 A JP2006500937 A JP 2006500937A JP 2006500937 A JP2006500937 A JP 2006500937A JP 2006516977 A5 JP2006516977 A5 JP 2006516977A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- group
- retching
- vomiting
- nausea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 malodors Substances 0.000 claims 19
- 206010028813 Nausea Diseases 0.000 claims 15
- 206010038776 Retching Diseases 0.000 claims 15
- 206010047700 Vomiting Diseases 0.000 claims 15
- 230000008693 nausea Effects 0.000 claims 15
- 230000008673 vomiting Effects 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 8
- 229960002430 atomoxetine Drugs 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 claims 6
- 229950001588 ramosetron Drugs 0.000 claims 6
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 5
- 206010002091 Anaesthesia Diseases 0.000 claims 5
- 206010019233 Headaches Diseases 0.000 claims 5
- 230000037005 anaesthesia Effects 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000002173 dizziness Diseases 0.000 claims 5
- 229960002866 duloxetine Drugs 0.000 claims 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 231100000869 headache Toxicity 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 231100000614 poison Toxicity 0.000 claims 5
- 230000035935 pregnancy Effects 0.000 claims 5
- 230000005855 radiation Effects 0.000 claims 5
- 239000003440 toxic substance Substances 0.000 claims 5
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 4
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 4
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 4
- 229940035676 analgesics Drugs 0.000 claims 4
- 239000000730 antalgic agent Substances 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 229940121375 antifungal agent Drugs 0.000 claims 4
- 229960003914 desipramine Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 4
- 229960004090 maprotiline Drugs 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229960000600 milnacipran Drugs 0.000 claims 4
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 4
- 229960001158 nortriptyline Drugs 0.000 claims 4
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960003770 reboxetine Drugs 0.000 claims 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 4
- 229960004688 venlafaxine Drugs 0.000 claims 4
- 229960001255 viloxazine Drugs 0.000 claims 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 3
- DBXKJORICFHAQA-UHFFFAOYSA-N 2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride Chemical compound Cl.CC1=NC=CN1CC1=CSC2=CC=C(C=CC=C3)C3=C2C1=O DBXKJORICFHAQA-UHFFFAOYSA-N 0.000 claims 3
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims 3
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims 3
- JCOJXICRPMRJPO-UHFFFAOYSA-N N-pent-3-yn-2-yloxybenzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC(C#CC)C JCOJXICRPMRJPO-UHFFFAOYSA-N 0.000 claims 3
- JJZXGTBGAPUCHC-PBWFPOADSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-ethyl-2-oxobenzimidazole-1-carboxylate Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1OC(=O)N1C2=CC=CC=C2N(CC)C1=O JJZXGTBGAPUCHC-PBWFPOADSA-N 0.000 claims 3
- 229960003550 alosetron Drugs 0.000 claims 3
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 229950005951 azasetron Drugs 0.000 claims 3
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 claims 3
- 229950007840 bemesetron Drugs 0.000 claims 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 229960003727 granisetron Drugs 0.000 claims 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 3
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims 3
- 229950007467 indisetron Drugs 0.000 claims 3
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims 3
- 229950007654 itasetron Drugs 0.000 claims 3
- AFOFVIBWSLOHFR-GOOCMWNKSA-N n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1NC(=O)N1C2=CC=CC=C2N(C(C)C)C1=O AFOFVIBWSLOHFR-GOOCMWNKSA-N 0.000 claims 3
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 claims 3
- 229960005343 ondansetron Drugs 0.000 claims 3
- 229960002131 palonosetron Drugs 0.000 claims 3
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 3
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims 3
- 229950003039 renzapride Drugs 0.000 claims 3
- 229960003688 tropisetron Drugs 0.000 claims 3
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 3
- 229950004681 zacopride Drugs 0.000 claims 3
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 claims 2
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 claims 2
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229950002371 lintopride Drugs 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 229950001074 zatosetron Drugs 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- SMCZVGWSWSDJPV-UHFFFAOYSA-N 2h-thiochromene 1-oxide Chemical compound C1=CC=C2S(=O)CC=CC2=C1 SMCZVGWSWSDJPV-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000000013 adrenergic uptake inhibitor Substances 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229960002099 cilansetron Drugs 0.000 claims 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229950008418 talipexole Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44007603P | 2003-01-13 | 2003-01-13 | |
| US49247803P | 2003-08-04 | 2003-08-04 | |
| PCT/US2004/000809 WO2004062624A2 (en) | 2003-01-13 | 2004-01-13 | Method of treating nausea, vomiting, retching or any combination thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516977A JP2006516977A (ja) | 2006-07-13 |
| JP2006516977A5 true JP2006516977A5 (https=) | 2007-02-08 |
Family
ID=32718144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500937A Pending JP2006516977A (ja) | 2003-01-13 | 2004-01-13 | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20040147510A1 (https=) |
| EP (1) | EP1567163B1 (https=) |
| JP (1) | JP2006516977A (https=) |
| KR (1) | KR20050094843A (https=) |
| AT (1) | ATE359079T1 (https=) |
| AU (1) | AU2004204827B2 (https=) |
| BR (1) | BRPI0406748A (https=) |
| CA (1) | CA2512022A1 (https=) |
| DE (1) | DE602004005814T2 (https=) |
| ES (1) | ES2285407T3 (https=) |
| MX (1) | MXPA05007379A (https=) |
| NZ (1) | NZ541009A (https=) |
| PL (1) | PL378369A1 (https=) |
| WO (1) | WO2004062624A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| AU2003259373B2 (en) * | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
| NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| US8598219B2 (en) * | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| EP1539181B1 (en) * | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
| WO2005007600A2 (en) * | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
| EP1708717B1 (en) * | 2003-07-28 | 2011-10-05 | Leslie Joe Dunaway | Atomoxetine for treatment of allergic rhinitis and asthma |
| US20050282879A1 (en) * | 2004-06-17 | 2005-12-22 | Foad Salehani | Methods and composition for treatment of migraine and symptoms thereof |
| EP1831173B1 (en) * | 2004-12-17 | 2011-01-26 | Janssen Pharmaceutica NV | Tetrahydroisoquinoline compounds for treatment of cns disorders |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| EP1983827A4 (en) * | 2006-02-01 | 2013-07-10 | Stuart L Weg | USE OF ANTIFUNGAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL CONDITIONS |
| US20070254899A1 (en) * | 2006-03-31 | 2007-11-01 | Dynogen Pharmaceuticals, Inc. | Soluble salts of thieno[2,3-d]pyrimidine derivatives |
| WO2007131070A2 (en) * | 2006-05-04 | 2007-11-15 | Xenoport, Inc. | Compositions, dosage forms and methods of treating emesis |
| WO2008038106A1 (en) * | 2006-09-27 | 2008-04-03 | Orchid Chemicals & Pharmaceuticals Limited | Venlafaxine extended release formulations |
| CN102458400B (zh) * | 2009-05-20 | 2014-10-08 | 国立健康与医学研究所 | 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂 |
| US9636305B2 (en) | 2013-03-14 | 2017-05-02 | Redhill Biopharma Ltd. | Antiemetic extended release solid dosage forms |
| SG11201607511WA (en) * | 2014-03-11 | 2016-10-28 | Redhill Biopharma Ltd | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms |
| RS65379B1 (sr) | 2016-04-14 | 2024-04-30 | Sensorion | (+)-azasetron za upotrebu u lečenju poremećaja uha |
| WO2022015628A2 (en) * | 2020-07-15 | 2022-01-20 | St. Jude Children's Research Hospital, Inc. | Obese ferret model and methods of establishing and using the same |
| WO2022232574A1 (en) | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023164132A1 (en) * | 2022-02-25 | 2023-08-31 | Neuraxis, Inc. | Auricular nerve field stimulation device and methods for using the same |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US44450A (en) * | 1864-09-27 | Improvement in ore-crushers | ||
| US254171A (en) * | 1882-02-28 | Car-axle box | ||
| US36500A (en) * | 1862-09-23 | Joseph banks | ||
| US107244A (en) * | 1870-09-13 | Improved manner of treating- cod-liver and castor-oils | ||
| US48874A (en) * | 1865-07-18 | Improved extension door-knobs | ||
| US203055A (en) * | 1878-04-30 | Improvement in carpet-stretchers | ||
| US36549A (en) * | 1862-09-23 | Improvement in caps | ||
| US254172A (en) * | 1882-02-28 | Half to laweence | ||
| US4225407A (en) * | 1979-04-04 | 1980-09-30 | The Dow Chemical Company | Cathodic electrodeposition of polymers onto a conductive surface |
| JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩 |
| DE201165T1 (de) * | 1985-03-14 | 1989-04-20 | Beecham Group P.L.C., Brentford | Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome". |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| DE3885357T2 (de) * | 1987-06-29 | 1994-03-24 | Duphar Int Res | Anellierte Indolderivate. |
| US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| CA1304082C (en) | 1987-10-22 | 1992-06-23 | Tetsuya Tahara | Benzoxazine compounds and pharmaceutical use thereof |
| US5530008A (en) * | 1989-04-21 | 1996-06-25 | Sandoz Ltd. | Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders |
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| WO1993000074A1 (en) * | 1991-06-26 | 1993-01-07 | Sepracor, Inc. | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| GB9214184D0 (en) | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH0616557A (ja) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | 脳機能障害改善剤 |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| DK0855397T3 (da) * | 1995-07-28 | 2001-06-25 | Dainippon Pharmaceutical Co | (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse |
| AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
| ES2208870T3 (es) * | 1996-02-15 | 2004-06-16 | Janssen Pharmaceutica N.V. | Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina. |
| CA2286076C (en) * | 1997-04-18 | 2006-12-12 | Janssen Pharmaceutica N.V. | Use of 5ht3 antagonists for promoting intestinal lavage |
| JPH10298078A (ja) | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | 抗不安薬 |
| ES2128266B1 (es) | 1997-07-08 | 2000-01-16 | Vita Invest Sa | Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes. |
| DE19813661A1 (de) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| DE19734444A1 (de) * | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
| US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
| ES2157107T3 (es) * | 1997-09-16 | 2001-08-01 | Solvay Pharm Gmbh | Uso de moxonidina para el tratamiento del dolor neuropatico. |
| US6117879A (en) * | 1997-09-16 | 2000-09-12 | Solvay Pharmaceuticals Gmbh | Methods of using moxonidine to inhibit nociceptive pain |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| FR2781671A1 (fr) | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
| ES2327600T3 (es) * | 1999-02-18 | 2009-11-02 | Novasearch Ag | Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas. |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| US6589570B1 (en) * | 1999-04-12 | 2003-07-08 | University Of Madras | Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
| DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| TWI263496B (en) | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| ES2188344B1 (es) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
| US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| GB0112494D0 (en) | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| WO2003061657A1 (en) | 2002-01-18 | 2003-07-31 | Aryx Therapeutics | 5-ht3 receptor antagonists and methods of use |
| GB0202265D0 (en) * | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
| JP2005526079A (ja) | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス， インコーポレイテッド | 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤 |
| CA2491836C (en) | 2002-07-10 | 2011-01-25 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| AU2003259373B2 (en) * | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
| WO2004058353A2 (en) | 2002-12-24 | 2004-07-15 | Paradigm Therapeutics Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
| NZ541009A (en) | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
-
2004
- 2004-01-13 NZ NZ541009A patent/NZ541009A/en unknown
- 2004-01-13 DE DE602004005814T patent/DE602004005814T2/de not_active Expired - Fee Related
- 2004-01-13 KR KR1020057012925A patent/KR20050094843A/ko not_active Withdrawn
- 2004-01-13 WO PCT/US2004/000809 patent/WO2004062624A2/en not_active Ceased
- 2004-01-13 US US10/757,981 patent/US20040147510A1/en not_active Abandoned
- 2004-01-13 CA CA002512022A patent/CA2512022A1/en not_active Abandoned
- 2004-01-13 MX MXPA05007379A patent/MXPA05007379A/es active IP Right Grant
- 2004-01-13 JP JP2006500937A patent/JP2006516977A/ja active Pending
- 2004-01-13 ES ES04701830T patent/ES2285407T3/es not_active Expired - Lifetime
- 2004-01-13 EP EP04701830A patent/EP1567163B1/en not_active Expired - Lifetime
- 2004-01-13 BR BR0406748-7A patent/BRPI0406748A/pt not_active IP Right Cessation
- 2004-01-13 PL PL378369A patent/PL378369A1/pl not_active Application Discontinuation
- 2004-01-13 AT AT04701830T patent/ATE359079T1/de not_active IP Right Cessation
- 2004-01-13 AU AU2004204827A patent/AU2004204827B2/en not_active Ceased
- 2004-05-14 US US10/846,978 patent/US20040254171A1/en not_active Abandoned
- 2004-05-14 US US10/846,979 patent/US7094786B2/en not_active Expired - Fee Related